The Shackelford Pharma Mission
Shackelford Pharma Inc. is focused on developing, obtaining regulatory approval for, and commercializing drugs to address neurological conditions.
Building on the pioneering work of Dr. Alan Shackelford and his treatment of over 25,000 patients to date, the company is developing therapies targeting the endocannabinoid system of the human body. This system, only discovered in recent decades, may play a critical role in
many important bodily functions and their dysfunction. The endocannabinoid system has been implicated in key neurological conditions such as seizures, headaches, and cognitive impairment.
Because little research has been done in this area to date, Shackelford Pharma believes that it has an exciting opportunity to address high unmet medical needs by developing novel drugs targeting the newly discovered endocannabinoid system. Ultimately offering hope to millions of
patients suffering with high unmet medical needs.
A world-class experienced team of entrepreneurs, scientists and pharmaceutical commercial personnel are backing Dr. Shackelford’s real-world clinical experience.
From Dr. Shackelford’s database, we have identified 30+ indications to date, over 20 of which are considered rare/orphan disorders. These potential indications were filtered for the best
commercial opportunities which are now being used to focus our product development efforts.
The intent of the company is to pursue development of pharmaceutical products (drug identification number) requiring full regulatory approval (FDA). Disorders with high unmet needs such as rare diseases and “Orphan" diseases are a development priority. Our R&D and Dr. Shackelford's clinical experience indicates that targeting the endocannabinoid system for drug development may provide viable options for millions of people with high unmet medical needs.
SPI is dedicated to alleviating human suffering through the development of pharmaceutical grade cannabinoid therapies for a range of unmet medical needs.
Our goal is to become the global leader in the development and commercialization of endocannabinoid targeted therapeutics.